You just read:

Seqirus presents analysis reinforcing the safety and immunogenicity profiles of its MF59®-adjuvanted seasonal trivalent influenza vaccine in adults 65 years and older

News provided by

Seqirus

Aug 26, 2016, 12:02 ET